Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortiumBastian Neesgaard, Lene Ryom, Jens Lundgren et al.|The Lancet HIV|2022Cited by 140
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortiumLoveleen Bansi‐Matharu, Lene Ryom, Andrew Phillips et al.|The Lancet HIV|2021Cited by 65
Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIVNadine Jaschinski, Lene Ryom, Lauren Greenberg et al.|AIDS|2022Cited by 38
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency VirusFrédérique Chammartin, Amanda Mocroft, Alexander Egle et al.|Clinical Infectious Diseases|2023Cited by 27
Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort StudyHortensia Álvarez, Amanda Mocroft, Lene Ryom et al.|Clinical Infectious Diseases|2023Cited by 23